South Korea
· Delayed Price · Currency is KRW WITHUS PHARMACEUTICAL Co.,LTD. Statistics
Total Valuation
WITHUS PHARMACEUTICAL Co.,LTD. has a market cap or net worth of KRW 92.55 billion. The enterprise value is 100.91 billion.
| Market Cap | 92.55B |
| Enterprise Value | 100.91B |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
WITHUS PHARMACEUTICAL Co.,LTD. has 13.20 million shares outstanding. The number of shares has increased by 0.16% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 13.20M |
| Shares Change (YoY) | +0.16% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 52.98% |
| Owned by Institutions (%) | n/a |
| Float | 6.09M |
Valuation Ratios
The trailing PE ratio is 13.75.
| PE Ratio | 13.75 |
| Forward PE | n/a |
| PS Ratio | 0.87 |
| PB Ratio | 1.00 |
| P/TBV Ratio | 1.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.43, with an EV/FCF ratio of -122.07.
| EV / Earnings | 15.01 |
| EV / Sales | 0.95 |
| EV / EBITDA | 8.43 |
| EV / EBIT | 12.12 |
| EV / FCF | -122.07 |
Financial Position
The company has a current ratio of 1.84, with a Debt / Equity ratio of 0.22.
| Current Ratio | 1.84 |
| Quick Ratio | 1.19 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | 1.69 |
| Debt / FCF | -24.45 |
| Interest Coverage | 10.36 |
Financial Efficiency
Return on equity (ROE) is 7.45% and return on invested capital (ROIC) is 4.73%.
| Return on Equity (ROE) | 7.45% |
| Return on Assets (ROA) | 4.08% |
| Return on Capital (ROIC) | 4.73% |
| Revenue Per Employee | 873.87M |
| Profits Per Employee | 55.58M |
| Employee Count | 121 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 2.81 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.48% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -30.48% |
| 50-Day Moving Average | 6,704.60 |
| 200-Day Moving Average | 7,630.80 |
| Relative Strength Index (RSI) | 59.08 |
| Average Volume (20 Days) | 39,680 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, WITHUS PHARMACEUTICAL Co.,LTD. had revenue of KRW 105.74 billion and earned 6.73 billion in profits. Earnings per share was 509.86.
| Revenue | 105.74B |
| Gross Profit | 67.40B |
| Operating Income | 8.32B |
| Pretax Income | 7.44B |
| Net Income | 6.73B |
| EBITDA | 11.97B |
| EBIT | 8.32B |
| Earnings Per Share (EPS) | 509.86 |
Balance Sheet
The company has 11.84 billion in cash and 20.21 billion in debt, giving a net cash position of -8.36 billion or -633.59 per share.
| Cash & Cash Equivalents | 11.84B |
| Total Debt | 20.21B |
| Net Cash | -8.36B |
| Net Cash Per Share | -633.59 |
| Equity (Book Value) | 92.59B |
| Book Value Per Share | 7,014.74 |
| Working Capital | 26.05B |
Cash Flow
In the last 12 months, operating cash flow was 3.80 billion and capital expenditures -4.63 billion, giving a free cash flow of -826.66 million.
| Operating Cash Flow | 3.80B |
| Capital Expenditures | -4.63B |
| Free Cash Flow | -826.66M |
| FCF Per Share | -62.62 |
Margins
Gross margin is 63.74%, with operating and profit margins of 7.87% and 6.36%.
| Gross Margin | 63.74% |
| Operating Margin | 7.87% |
| Pretax Margin | 7.04% |
| Profit Margin | 6.36% |
| EBITDA Margin | 11.32% |
| EBIT Margin | 7.87% |
| FCF Margin | n/a |
Dividends & Yields
WITHUS PHARMACEUTICAL Co.,LTD. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 19.61% |
| Buyback Yield | -0.16% |
| Shareholder Yield | -0.16% |
| Earnings Yield | 7.27% |
| FCF Yield | -0.89% |
Stock Splits
The last stock split was on June 11, 2021. It was a forward split with a ratio of 1.5.
| Last Split Date | Jun 11, 2021 |
| Split Type | Forward |
| Split Ratio | 1.5 |
Scores
WITHUS PHARMACEUTICAL Co.,LTD. has an Altman Z-Score of 3.84.
| Altman Z-Score | 3.84 |
| Piotroski F-Score | n/a |